Novartis Oncology Director of Business Development Salaries in Wilmington, DE
The average Novartis Oncology Director of Business Development in Wilmington, DE earns an estimated $216,082 annually, which includes an estimated base salary of $166,335 with a $49,747 bonus. Novartis Oncology's Director of Business Development compensation is $49,816 more than the US average for a Director of Business Development. Director of Business Development salaries at Novartis Oncology in Wilmington, DE can range from $73,000 - $390,000.
In Wilmington, DE, The Business Development Department at Novartis Oncology earns $129 more on average than the Engineering Department.
Last updated 3 years ago.
- $166,335
- avg. base
- $49,747
- avg. bonus
Director of Business Development Salaries at Novartis Oncology
In Wilmington, DE, Directors of Business Development earn $3,756 more than Directors of Business Development.
Compensation at Novartis Oncology by Department
In Wilmington, DE, The Business Development Department averages $129 more than the Engineering Department, and $3,227 less than the Operations Department
Director of Business Development Compensation by Gender (All Companies)
The average female Director of Business Development at companies similar size to Novartis Oncology reported making $205,320, while the average male Director of Business Development at similar sized companies reported making $214,912.
Director of Business Development Compensation by Ethnicity (All Companies)
The average African American/Black Director of Business Development at companies similar size to Novartis Oncology reported making $217,667, while the average Hispanic or Latino Director of Business Development at similar sized companies reported making $185,667.
How Directors of Business Development at Novartis Oncology Rate Their Compensation
The majority of Directors of Business Development at Novartis Oncology believe they're not compensated fairly. 100% of Directors of Business Development at Novartis Oncology say they receive annual bonuses, and the vast majority (83%) are satisfied with their benefits. See more compensation ratings at Novartis Oncology
